Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Final Analysis of the GioTag Study

References

• FDA . Tarceva® (erlotinib), prescribing information. (2016). https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf
   Google Scholar
• AstraZeneca . Iressa® (gefitinib), prescribing information. (2015). https://www.azpicentral.com/iressa/iressa.pdf
   Google Scholar
• FDA . Gilotrif® (afatinib), prescribing information. (2018). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf
   Google Scholar
• Pfizer . Vizimpro® Tablets (dacomitinib), prescribing information. (2018). http://labeling.pfizer.com/ShowLabeling.aspx?format=PDF&id=11019
   Google Scholar
• FDA . Tagrisso® (osimertinib), prescribing information. (2018). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf
   Google Scholar
• Park K , TanE-H, O’ByrneKet al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a Phase IIB, open-label, randomised controlled trial. Lancet Oncol.17(5), 577–589 (2016).
   PubMed Web of Science ®Google Scholar
• Wu YL , ChengY, ZhouXet al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol.18(11), 1454–1466 (2017).
   PubMed Web of Science ®Google Scholar
• Soria JC , OheY, VansteenkisteJet al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med.378(2), 113–125 (2018).
   PubMed Web of Science ®Google Scholar
• Mok TS , ChengY, ZhouXet al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J. Clin. Oncol.36(22), 2244–2250 (2018).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L , TanE-H, O’ByrneKet al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the Phase IIb LUX-Lung 7 trial. Ann. Oncol.28(2), 270–277 (2017).
   PubMed Web of Science ®Google Scholar
• Ramalingam SS , VansteenkisteJ, PlanchardDet al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med.382(1), 41–50 (2020).
   PubMed Web of Science ®Google Scholar
• Arcila ME , OxnardGR, NafaKet al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin. Cancer Res.17(5), 1169–1180 (2011).
   PubMed Web of Science ®Google Scholar
• Sequist LV , WaltmanBA, Dias-SantagataDet al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med.3(75), 75ra26 (2011).
   PubMed Web of Science ®Google Scholar
• Yang JC , AhnM-J, KimD-Wet al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study Phase II extension component. J. Clin. Oncol.35(12), 1288–1296 (2017).
   PubMed Web of Science ®Google Scholar
• Hochmair MJ , BuderA, SchwabSet al. Liquid-biopsy-based identification of EGFR T790M mutation-mediated resistance to afatinib treatment in patients with advanced EGFR mutation-positive NSCLC, and subsequent response to osimertinib. Target Oncol.14(1), 75–83 (2019).
   PubMed Web of Science ®Google Scholar
• Jenkins S , YangJC-H, RamalingamSSet al. Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small-cell lung cancer. J. Thorac. Oncol.12(7), 1061–1070 (2017).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuY-L, AhnM-Jet al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med.376(7), 629–640 (2017).
   PubMed Web of Science ®Google Scholar
• Oxnard GR , HuY, MilehamKFet al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol.4(11), 1527–1534 (2018).
   PubMed Web of Science ®Google Scholar
• Niederst MJ , HuH, MulveyHEet al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res.21(17), 3924–3933 (2015).
   PubMed Web of Science ®Google Scholar
• Hochmair MJ , MorabitoA, HaoDet al. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Future Oncol.14(27), 2861–2874 (2018).
   PubMed Web of Science ®Google Scholar
• Hochmair MJ , MorabitoA, HaoDet al. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol.15(25), 2905–2914 (2019).
   PubMed Web of Science ®Google Scholar
• Roviello G , ZanottiL, CappellettiMRet al. Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small-cell lung cancer? Clin. Exp. Med. 18(1), 15–20 (2018).
   PubMed Web of Science ®Google Scholar
• Park K , BennounaJ, BoyerMet al. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small-cell lung cancer. Lung Cancer132, 126–131 (2019).
   PubMed Web of Science ®Google Scholar
• Tamiya M , TamiyaA, SuzukiHet al. Which is better EGFR-TKI followed by osimertinib: afatinib or gefitinib/erlotinib? Anticancer Res. 39(7), 3923–3929 (2019).
   PubMed Web of Science ®Google Scholar
• Nogami N , RamalingamSS, ImamuraFet al. PS-1 Osimertinib as first-line therapy for EGFRm advanced NSCLC (FLAURA): final OS in Japanese subset. Presented at: The 60th Annual Meeting of the Japanese Lung Cancer Society. (2019). https://www.haigan.gr.jp/journal/am/2019a/19a_pdsy0000PS-1.html
   Google Scholar
• Wu Y , MokTSK, HanJ-Yet al. Overall survival (OS) from the AURA3 Phase III study: osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI). Ann.Oncol.30(Suppl. 9), ix157–ix181 (2019).
   Google Scholar
• Remon J , CaramellaC, JoveletCet al. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. Ann. Oncol.28(4), 784–790 (2017).
   PubMed Web of Science ®Google Scholar